8-K/A: iSpecimen Amends Series C Preferred Stock Terms

iSpecimen Inc. has amended the terms of its Series C Convertible Non-Voting Preferred Stock to include proportionate adjustments for conversion and floor prices following stock splits or combinations.

Summary

• iSpecimen Inc. filed an Amendment No. 1 on Form 8-K/A to its Current Report on Form 8-K, originally filed on January 2, 2026.
• The amendment, filed on January 16, 2026, modifies the Certificate of Designation for the Series C Convertible Non-Voting Preferred Stock.
• Specifically, Section 7 of the Original Certificate of Designation was amended to provide that both the Conversion Price and the Floor Price of the Series C Preferred Stock will be proportionately adjusted.
• These adjustments will occur upon any reverse stock split, share combination, or similar transaction that results in a decrease in the number of outstanding shares of the company's common stock.
• The amendment was approved by the Company and the holders of more than a majority (50.1%) of the outstanding shares of the Series C Preferred Stock.

Sentiment

Score: 6

Explanation: The filing is a neutral, technical amendment to clarify terms of existing preferred stock. It resolves a potential ambiguity, which is a minor positive for corporate governance, but has no direct impact on financial performance or strategic direction.

Positives

• The amendment clarifies the adjustment mechanisms for the Series C Preferred Stock's conversion and floor prices, providing greater certainty for investors in the event of corporate actions like stock splits.
• The amendment was approved by a majority of Series C Preferred Stock holders, indicating alignment between the company and these investors regarding the terms.

Future Outlook

NA

Management Comments

• The Corporation deems it advisable and in the best interests of the Corporation and its stockholders to amend the Certificate of Designation solely to amend Section 7 thereof, and no other provision of the Certificate of Designation.

Industry Context

This filing represents a technical corporate governance amendment, which is a standard practice for companies to clarify the terms of their issued securities. It does not directly relate to broader industry trends, competitive landscape, or operational performance within the biotechnology or specimen procurement sectors.

Corporate Governance

Stakeholder Impact

• Shareholders (Series C Preferred Stock holders): Provides clarity and protection regarding the value of their conversion and floor prices in the event of common stock structural changes.
• Common Stockholders: Indirectly impacts common stockholders by clarifying the terms under which preferred stock can convert, especially during events like reverse stock splits which affect common share count.

Key Dates

Keywords

iSpecimen Inc., ISPC, SEC Filing, 8-K/A, Preferred Stock, Series C Convertible Preferred Stock, Certificate of Designation, Stock Split, Corporate Governance, Conversion Price, Floor Price